

Attention Business Editors:

Welichem Begins Patient Enrollment for Phase IIa Trial of WBI-1001 Cream
in Patients with Psoriasis

VANCOUVER, Feb. 24 /CNW/ - Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.

It is planned that 60 patients (20 placebo and 40 active treatment) will be enrolled in the trial that is anticipated to be concluded in 7 to 9 months.

ON BEHALF OF THE BOARD

Dr. Xiangdong Tan, Chairman of the Board

<<

About Welichem Biotech Inc.

>>

Welichem Biotech Inc. is a company developing therapeutic drugs in the fields of inflammatory/autoimmune diseases and cancer.

%SEDAR: 00021386E

/For further information: Liren Tang, PhD., Chief Executive Officer,
Tel.: (604) 432-1703, Email:lirentang(at)welichem.com/
(WBI.)

CO: Welichem Biotech Inc.

CNW 13:27e 24-FEB-10